{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:1674",
      "entity_text" : "MC",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02327",
      "entity_text" : "anti-IgE recombinant humanized monoclonal antibody omalizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In refractory cases despite conventional therapy, treatment with the anti-IgE recombinant humanized monoclonal antibody omalizumab has shown to suppress MC activation episodes in all clinical subtypes of MCAS presenting as idiopathic anaphylaxis, Meniere 's disease, and also to prevent reactions related to venom immunotherapy administration.",
  "reading_complete" : "2020-08-04T11:13:06Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T11:10:34Z",
  "trigger" : "suppress",
  "evidence" : [ "anti-IgE recombinant humanized monoclonal antibody omalizumab has shown to suppress MC" ],
  "pmc_id" : "5502410",
  "score" : 0
}